Quick Answer
Spyre Therapeutics, Inc. reported Operating Income of -$209.56 million for fiscal year 2025.
Spyre Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$209.56M | -0.5% |
| 2024 | -$208.57M | +13.9% |
| 2023 | -$242.30M | -185.8% |
| 2022 | -$84.78M | -29.1% |
| 2021 | -$65.65M | +19.4% |
| 2020 | -$81.48M | -1.4% |
| 2019 | -$80.33M | -76.7% |
| 2018 | -$45.46M | -64.3% |
| 2017 | -$27.68M | -26.3% |
| 2016 | -$21.91M | -93.6% |
| 2015 | -$11.31M | -27.1% |
| 2014 | -$8.90M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$56.89M | -2.7% | -35.7% |
| June 30, 2025 | -$41.94M | +5.0% | +21.7% |
| March 31, 2025 | -$53.57M | -12.1% | +3.3% |
| September 30, 2024 | -$55.39M | -202.1% | -25.5% |
| June 30, 2024 | -$44.15M | +72.3% | +7.6% |
| March 31, 2024 | -$47.77M | -154.0% | -160.5% |
| September 30, 2023 | -$18.34M | +2.2% | +88.5% |
| June 30, 2023 | -$159.25M | -610.2% | -746.8% |
- Spyre Therapeutics, Inc. showed a decrease of -0.5% in Operating Income compared to the prior fiscal year.
- Over the 2014–2025 period, Spyre Therapeutics, Inc.’s operating income has declined by 2253.6% (from -$8.90 million to -$209.56 million).
- The most recent figure is from Spyre Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: